login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SUTRO BIOPHARMA INC (STRO) Stock News
USA
- NASDAQ:STRO -
US8693671021
-
Common Stock
0.8466
USD
-0.06 (-6.97%)
Last: 11/20/2025, 8:00:00 PM
0.85
USD
+0 (+0.4%)
After Hours:
11/20/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
STRO Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
14 days ago - By: Zacks Investment Research
- Mentions:
DARE
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
15 days ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
16 days ago - By: Sutro Biopharma, Inc.
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
17 days ago - By: Zacks Investment Research
- Mentions:
SNDX
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
18 days ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
7 months ago - By: Benzinga
Demystifying Sutro Biopharma: Insights From 4 Analyst Reviews
8 months ago - By: Benzinga
- Mentions:
LI
FSK
RLX
CION
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
2 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
4 months ago - By: Zacks Investment Research
- Mentions:
ANIP
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
4 months ago - By: Zacks Investment Research
- Mentions:
CYTK
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
4 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
7 months ago - By: Zacks Investment Research
- Mentions:
FHTX
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
7 months ago - By: Zacks Investment Research
- Mentions:
EYPT
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: Zacks Investment Research
- Mentions:
CRSP
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
7 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma to Participate in Upcoming Investor Conferences
7 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
8 months ago - By: Sutro Biopharma, Inc.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Please enable JavaScript to continue using this application.